Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s Disease
Inflammatory Bowel Diseases · 01.08.2024 · 30 (8) · 1295-1302
DOI: 10.1093/ibd/izad184 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 24.08.2023. Verfasst von Haixia Ren und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuhan 430060, Hubei Province, China. Hauptthemen laut MEDLINE: Crohn Disease, Ustekinumab. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Emergency Scientific Research Project of Wuhan Municipal Health Commission, Teaching and Research Project of Wuhan University School of Medicine.
Abstract (Originalsprache)
Background
Although increasing studies have reported that dose escalation can improve treatment response to ustekinumab in patients with Crohn’s disease (CD), their strategies mainly focus on maintenance regimen. Evidence of ustekinumab dose escalation in induction regimen, particularly in severe CD, remains limited. This study evaluated the efficacy and safety of intravenous ustekinumab with 2 initial doses in patients with severely active CD.
Methods
A retrospective observational study of 99 adult patients with severe CD treated with ustekinumab from 3 IBD centers included 48 patients with standard and 51 with optimized induction treatment. Clinical outcomes, inflammatory biomarkers including fecal calprotectin (FC) normalization, and endoscopic outcomes were evaluated at weeks 16 and 48. Adverse events and treatment decisions after initial induction were also collected.
Results
Compared with the standard group, 2 initial intravenous injections of ustekinumab achieved higher clinical response (92.2%, 47 of 51, P = .656), clinical remission (88.2%, 45 of 51, P = .221), endoscopic response (75.8%, 25 of 33, P = .125), and FC normalization (70.6%, 36 of 51, P = .138) at week 16. The mucosal healing rate at week 16 (63.6%, P = .022) was statistically higher in the optimization group. At week 48, patients with optimized treatment achieved higher clinical response (80.4%, 41 of 51, P = .003), clinical remission (70.6%, 36 of 51, P = .007), FC normalization (66.7%, 34 of 51, P = .031), endoscopic response (72.7%, 24 of 33, P = .006), and mucosal healing (57.6%, 19 of 33, P = .004). At the last follow-up, 82.4% of optimally treated patients adhered to continued treatment with ustekinumab (P < .001).
Conclusions
Optimization of ustekinumab by 2 initial intravenous inductions is more effective than standard therapy for adult patients with severe CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuhan 430060, Hubei Province, China.
- Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
- Hubei Provincial Clinical Research Center for Digestive Disease Minimally Invasive Incision, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
- Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China.
- Department of Gastroenterology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China.
- Sports Rehabilitation, College of Sport Medicine, Wuhan Sports University, Wuhan 430079, Hubei Province, China.
ORCID-Profile: Weiguo Dong, Ping An
Förderung
- National Natural Science Foundation of China
- Emergency Scientific Research Project of Wuhan Municipal Health Commission
- Teaching and Research Project of Wuhan University School of Medicine
- Interdisciplinary Innovative Talents Foundation
- Clinical Nursing Special Research Incubation Foundation
Zitieren
APA
Ren, H., Kang, J., Wang, J., Su, J., Zou, L., Yin, A., Li, J., Zhou, Q., Wang, W., Tang, Z., Zhang, J., Lu, Y., Yang, Y., Qiu, C., Ding, Y., Dong, W., & An, P. (2024). Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s Disease. Inflammatory Bowel Diseases, 30(8), 1295-1302. https://doi.org/10.1093/ibd/izad184
Vancouver
Ren H, Kang J, Wang J, Su J, Zou L, Yin A, et al. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s Disease. Inflammatory Bowel Diseases. 2024;30(8):1295-1302. doi:10.1093/ibd/izad184
BibTeX
@article{Ren2024,
author = {Ren, Haixia and Kang, Jian and Wang, Jing and Su, Juan and Zou, Liping and Yin, Anning and Li, Jiao and Zhou, Qian and Wang, Wei and Tang, Zhishun and Zhang, Jing and Lu, Yueyue and Yang, Yuanping and Qiu, Chengen and Ding, Yijuan and Dong, Weiguo and An, Ping},
title = {Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2024},
volume = {30},
number = {8},
pages = {1295--1302},
doi = {10.1093/ibd/izad184}
}
EUVIMED